Changing the Trajectory of Heart Failure and Kidney Disease: A Call for Action

Authors

Janani Rangaswami, Division of Nephrology, George Washington University School of Medicine, Washington, DC rangajanani@mfa.gwu.edu.
Vivek Bhalla, Division of Nephrology, Stanford University School of Medicine, Stanford, California.
Glenn M. Chertow, Division of Nephrology, Stanford University School of Medicine, Stanford, California.
Robert A. Harrington, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Alexander Staruschenko, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida.
Katherine Tuttle, Providence Medical Research Center, Providence Health Care, Spokane, Washington.
Eugene Braunwald, Thrombolysis in Myocardial Infarction Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Document Type

Journal Article

Publication Date

3-1-2022

Journal

Clinical journal of the American Society of Nephrology : CJASN

DOI

10.2215/CJN.00470122

Keywords

SGLT2 inhibitors; cardiorenal; heart failure; multidisciplinary

APA Citation

Rangaswami, Janani; Bhalla, Vivek; Chertow, Glenn M.; Harrington, Robert A.; Staruschenko, Alexander; Tuttle, Katherine; and Braunwald, Eugene, "Changing the Trajectory of Heart Failure and Kidney Disease: A Call for Action" (2022). GW Authored Works. Paper 655.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/655

Department

Medicine